Cargando…

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is a specific subtype of peripheral T cell lymphoma (PTCL) with a poor prognosis. To date, there exist no standard therapeutic regimens for relapsed/refractory (R/R) ENKTL. More potent treatment strategies are urgently needed to impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Lijun, Zhang, Lei, Li, Ling, Li, Xin, Yan, Jiaqin, Wang, Xinhua, Fu, Xiaorui, Sun, Zhenchang, Zhang, Xudong, Li, Zhaoming, Wu, Jingjing, Yu, Hui, Chang, Yu, Zhou, Zhiyuan, Nan, Feifei, Wu, Xiaolong, Tian, Li, Zhang, Mingzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394590/ https://www.ncbi.nlm.nih.gov/pubmed/32801749 http://dx.doi.org/10.2147/OTT.S262039

Ejemplares similares

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
por: Sun, Yuanyuan, et al.
Publicado: (2020)

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial
por: Wang, Yawen, et al.
Publicado: (2022)

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
por: Zhang, Xudong, et al.
Publicado: (2018)

MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma
por: Zhang, Xudong, et al.
Publicado: (2016)

AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma
por: Yan, Jiaqin, et al.
Publicado: (2018)

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma
por: Li, Zhaoming, et al.
Publicado: (2019)

Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase
por: Chang, Yu, et al.
Publicado: (2017)

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial
por: Wu, Jingjing, et al.
Publicado: (2018)

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma
por: Li, Ling, et al.
Publicado: (2018)

Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
por: Zhang, Lei, et al.
Publicado: (2016)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
por: Ma, Xinran, et al.
Publicado: (2020)

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
por: Liu, Xiangli, et al.
Publicado: (2019)

Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report
por: HAN, LIJUAN, et al.
Publicado: (2014)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
por: Ren, Liangliang, et al.
Publicado: (2021)

Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Shi, Zhuangzhuang, et al.
Publicado: (2021)

Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review
por: Lin, Li, et al.
Publicado: (2017)

Recurrent PDGFRB mutations in unicentric Castleman disease
por: Li, Zhaoming, et al.
Publicado: (2019)

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019)

P1240: ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL
por: Zhang, L., et al.
Publicado: (2022)

Phosphatase and tensin homolog (PTEN) is down-regulated in human NK/T-cell lymphoma and corrects with clinical outcomes
por: Fu, Xiaorui, et al.
Publicado: (2017)

Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
por: Wu, Jingjing, et al.
Publicado: (2022)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Multi PCET in symmetrically substituted benzimidazoles
por: Odella, Emmanuel, et al.
Publicado: (2021)

S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine
por: Zhou, Zhiyuan, et al.
Publicado: (2016)

B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma
por: Wang, Gangjian, et al.
Publicado: (2019)

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma
por: HAN, LIJUAN, et al.
Publicado: (2014)

DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
por: Wang, Xin, et al.
Publicado: (2020)

Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy
por: Lin, Qingqing, et al.
Publicado: (2023)

Multisite PCET with photocharged carbon nitride in dark
por: Mazzanti, Stefano, et al.
Publicado: (2021)

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
por: Nan, Feifei, et al.
Publicado: (2022)

T-cell dysfunction in natural killer/T-cell lymphoma
por: Feng, Xiaoyan, et al.
Publicado: (2023)

TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway
por: Zhu, Linan, et al.
Publicado: (2018)

P1133: CHIDAMIDE PLUS PREDNISONE, CYCLOPHOSPHAMIDE, AND THALIDOMIDE (CPCT) FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER PHASE II TRIAL
por: Liang, Jinhua, et al.
Publicado: (2023)

Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review
por: Fu, Xiaorui, et al.
Publicado: (2018)

Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate
por: Zhou, Zhiyuan, et al.
Publicado: (2021)

Clinical features and prognostic factors of primary bone marrow lymphoma
por: Wang, Gangjian, et al.
Publicado: (2019)

Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on (18)F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma
por: Feng, Xiaoyan, et al.
Publicado: (2021)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang, Fangwen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9orarvc894j5ffne0q1880fhtk